United Therapeutics Authorizes Another $2 Billion Buyback, Separate From Its Running Repurchase

The new program runs through October 21, 2027 and sets no minimum purchase, while a September accelerated repurchase continues.

Share
United Therapeutics Authorizes Another $2 Billion Buyback, Separate From Its Running Repurchase

United Therapeutics' board approved a new share repurchase program of up to $2.0 billion on October 21, according to an 8-K the company filed Thursday. The authorization stays in effect for one year, ending October 21, 2027.

What the filing says

The 8-K, filed under Item 8.01 (other events), says the board approved the program on October 21. The company issued a press release announcing it on October 22.

Purchases can be made through accelerated share repurchase programs, open-market trades, privately negotiated deals or other means. The program requires no minimum number of shares, and any buying is at the company's discretion, depending on alternative uses of capital, market conditions and other factors.

The company may start or suspend purchases at any time without prior notice and assumes no obligation to use the authorization.

What it changes

The new authorization sits alongside a buyback already under way. The company has an accelerated share repurchase, or ASR, entered into in September 2026 under its prior authorization. It has a scheduled termination date in the fourth quarter of 2026, subject to earlier termination or extension under its terms.

The release says the ASR will not reduce the amount available under the new authorization, so the full $2 billion is separate capacity.

CFO and Treasurer James Edgemond said the company has "the balance sheet and free cash flow to fund our long-term ambitions" and the "confidence to act decisively when our own shares represent a compelling investment."

UTHR shares closed at $563.49 at Wednesday's close, up about 2% on the session, before the filing was accepted Thursday at 7:00 a.m. ET.

The running ASR is the next dated item: it is scheduled to terminate in the fourth quarter of 2026, unless ended early or extended.

Sources

More on United Therapeutics

All United Therapeutics (UTHR) coverage →